$116 Million is the total value of Opus Point Partners Management, LLC's 65 reported holdings in Q4 2017. The portfolio turnover from Q3 2017 to Q4 2017 was 11.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SAGE | New | SAGE THERAPEUTICS INCput | $11,694,000 | – | 71,000 | +100.0% | 10.12% | – |
| BIB | PROSHARES TR | $7,317,000 | -8.5% | 130,500 | 0.0% | 6.33% | -11.7% | |
| XBI | SPDR SERIES TRUSTs&p biotech | $5,517,000 | -2.0% | 65,000 | 0.0% | 4.77% | -5.5% | |
| BMY | BRISTOL MYERS SQUIBB CO | $5,515,000 | -3.9% | 90,000 | 0.0% | 4.77% | -7.3% | |
| NKTR | Sell | NEKTAR THERAPEUTICS | $5,498,000 | +119.6% | 92,070 | -11.7% | 4.76% | +111.7% |
| ALNY | Sell | ALNYLAM PHARMACEUTICALS INC | $5,471,000 | -1.9% | 43,064 | -9.3% | 4.73% | -5.4% |
| MRK | MERCK & CO INC | $4,710,000 | -12.1% | 83,700 | 0.0% | 4.07% | -15.3% | |
| RXDX | IGNYTA INC | $4,552,000 | +116.1% | 170,500 | 0.0% | 3.94% | +108.4% | |
| ALXN | ALEXION PHARMACEUTICALS INCcall | $4,186,000 | -14.7% | 35,000 | 0.0% | 3.62% | -17.8% | |
| AZN | ASTRAZENECA PLCsponsored adr | $4,164,000 | +2.4% | 120,000 | 0.0% | 3.60% | -1.3% | |
| PFE | PFIZER INC | $4,068,000 | +1.5% | 112,300 | 0.0% | 3.52% | -2.2% | |
| IBB | Buy | ISHARES TRnasdaq biotech | $4,004,000 | -4.0% | 37,500 | +200.0% | 3.46% | -7.4% |
| BMY | BRISTOL MYERS SQUIBB COcall | $2,758,000 | -3.9% | 45,000 | 0.0% | 2.39% | -7.3% | |
| VRTX | Sell | VERTEX PHARMACEUTICALS INC | $2,494,000 | -10.2% | 16,639 | -8.9% | 2.16% | -13.4% |
| ALKS | Sell | ALKERMES PLC | $2,395,000 | -2.4% | 43,763 | -9.3% | 2.07% | -5.9% |
| MTD | METTLER TOLEDO INTERNATIONAL | $2,227,000 | -1.0% | 3,594 | 0.0% | 1.93% | -4.6% | |
| GSK | GLAXOSMITHKLINE PLCsponsored adr | $2,128,000 | -12.6% | 60,000 | 0.0% | 1.84% | -15.8% | |
| ILMN | Sell | ILLUMINA INC | $2,123,000 | -5.1% | 9,717 | -13.5% | 1.84% | -8.6% |
| IONS | Sell | IONIS PHARMACEUTICALS INC | $1,981,000 | -11.6% | 39,388 | -10.9% | 1.71% | -14.7% |
| SGEN | Sell | SEATTLE GENETICS INC | $1,908,000 | -15.0% | 35,668 | -13.6% | 1.65% | -18.1% |
| BIIB | Sell | BIOGEN INC | $1,845,000 | -11.9% | 5,793 | -13.4% | 1.60% | -15.1% |
| QGEN | Sell | QIAGEN NV | $1,746,000 | -13.9% | 56,445 | -12.4% | 1.51% | -17.0% |
| INCY | Sell | INCYTE CORP | $1,735,000 | -26.2% | 18,318 | -9.1% | 1.50% | -28.9% |
| AMGN | Sell | AMGEN INC | $1,726,000 | -18.9% | 9,924 | -13.0% | 1.49% | -21.8% |
| AGIO | Sell | AGIOS PHARMACEUTICALS INC | $1,641,000 | -26.3% | 28,704 | -13.9% | 1.42% | -28.9% |
| REGN | Sell | REGENERON PHARMACEUTICALS | $1,532,000 | -24.9% | 4,076 | -10.6% | 1.32% | -27.6% |
| BMRN | Sell | BIOMARIN PHARMACEUTICAL INC | $1,526,000 | -17.7% | 17,118 | -14.1% | 1.32% | -20.7% |
| CELG | Sell | CELGENE CORP | $1,517,000 | -35.7% | 14,540 | -10.1% | 1.31% | -38.0% |
| LLY | LILLY ELI & COcall | $1,267,000 | -1.2% | 15,000 | 0.0% | 1.10% | -4.8% | |
| LOXO | LOXO ONCOLOGY INC | $1,162,000 | -8.6% | 13,800 | 0.0% | 1.00% | -11.8% | |
| ALXN | Sell | ALEXION PHARMACEUTICALS INC | $1,143,000 | -28.8% | 9,558 | -16.5% | 0.99% | -31.4% |
| PCRX | PACIRA PHARMACEUTICALS INC | $1,141,000 | +21.5% | 25,000 | 0.0% | 0.99% | +17.2% | |
| CLVS | CLOVIS ONCOLOGY INC | $1,020,000 | -17.5% | 15,000 | 0.0% | 0.88% | -20.5% | |
| ADMS | ADAMAS PHARMACEUTICALS INC | $1,017,000 | +60.2% | 30,000 | 0.0% | 0.88% | +54.4% | |
| PRQR | New | PROQR THRAPEUTICS N V | $992,000 | – | 307,692 | +100.0% | 0.86% | – |
| KPTI | KARYOPHARM THERAPEUTICS INC | $960,000 | -12.6% | 100,000 | 0.0% | 0.83% | -15.7% | |
| AXSM | AXSOME THERAPEUTICS INC | $748,000 | +0.9% | 133,500 | 0.0% | 0.65% | -2.7% | |
| PRTK | PARATEK PHARMACEUTICALS INC | $716,000 | -28.7% | 40,000 | 0.0% | 0.62% | -31.3% | |
| GILD | GILEAD SCIENCES INCcall | $716,000 | -11.6% | 10,000 | 0.0% | 0.62% | -14.9% | |
| CKPT | CHECKPOINT THERAPEUTICS INC | $438,000 | -13.6% | 112,760 | 0.0% | 0.38% | -16.7% | |
| TSRO | TESARO INC | $414,000 | -35.9% | 5,000 | 0.0% | 0.36% | -38.3% | |
| RARE | Sell | ULTRAGENYX PHARMACEUTICAL IN | $393,000 | -38.0% | 8,472 | -28.8% | 0.34% | -40.2% |
| MDCO | MEDICINES CO | $383,000 | -26.2% | 14,000 | 0.0% | 0.33% | -29.0% | |
| BIVV | Sell | BIOVERATIV INC | $361,000 | -42.8% | 6,689 | -39.5% | 0.31% | -44.9% |
| NBIX | Sell | NEUROCRINE BIOSCIENCES INC | $326,000 | -44.8% | 4,204 | -56.4% | 0.28% | -46.8% |
| SNR | NEW SR INVT GROUP INC | $316,000 | -17.5% | 41,850 | 0.0% | 0.27% | -20.6% | |
| AKBA | AKEBIA THERAPEUTICS INC | $312,000 | -24.5% | 21,009 | 0.0% | 0.27% | -27.2% | |
| UTHR | Sell | UNITED THERAPEUTICS CORP DEL | $303,000 | -37.0% | 2,050 | -50.1% | 0.26% | -39.4% |
| HRTX | HERON THERAPEUTICS INC | $287,000 | +12.1% | 15,874 | 0.0% | 0.25% | +7.8% | |
| AVXS | AVEXIS INC | $277,000 | +14.5% | 2,500 | 0.0% | 0.24% | +10.6% | |
| GRFS | Sell | GRIFOLS S Asp adr rep b nvt | $265,000 | -51.2% | 11,565 | -53.4% | 0.23% | -53.0% |
| TECH | Sell | BIO TECHNE CORP | $257,000 | -50.2% | 1,987 | -53.4% | 0.22% | -52.1% |
| JUNO | Sell | JUNO THERAPEUTICS INC | $255,000 | -61.4% | 5,588 | -62.0% | 0.22% | -62.7% |
| IQV | New | IQVIA HLDGS INC | $236,000 | – | 2,415 | +100.0% | 0.20% | – |
| CRL | Sell | CHARLES RIV LABS INTL INC | $236,000 | -55.9% | 2,154 | -56.5% | 0.20% | -57.5% |
| REPH | RECRO PHARMA INC | $233,000 | +2.6% | 25,231 | 0.0% | 0.20% | -1.0% | |
| ICPT | Sell | INTERCEPT PHARMACEUTICALS IN | $221,000 | -15.0% | 3,779 | -15.7% | 0.19% | -18.0% |
| GILD | Sell | GILEAD SCIENCES INC | $220,000 | -58.0% | 3,075 | -52.4% | 0.19% | -59.6% |
| FGEN | New | FIBROGEN INC | $210,000 | – | 4,423 | +100.0% | 0.18% | – |
| ACAD | Sell | ACADIA PHARMACEUTICALS INC | $207,000 | -64.9% | 6,880 | -56.0% | 0.18% | -66.1% |
| XON | Sell | INTREXON CORP | $164,000 | -64.0% | 14,221 | -40.6% | 0.14% | -65.2% |
| SCYX | SCYNEXIS INC | $155,000 | -3.7% | 66,608 | 0.0% | 0.13% | -6.9% | |
| CFRX | CONTRAFECT CORP | $152,000 | -9.0% | 150,000 | 0.0% | 0.13% | -12.7% | |
| PGNX | PROGENICS PHARMACEUTICALS IN | $130,000 | -18.8% | 21,782 | 0.0% | 0.11% | -22.2% | |
| LGND | Exit | LIGAND PHARMACEUTICALS INC | $0 | – | -1,519 | -100.0% | -0.19% | – |
| Q | Exit | QUINTILES IMS HOLDINGS INC | $0 | – | -5,413 | -100.0% | -0.46% | – |
| LABU | Exit | DIREXION SHS ETF TRsp biotch bl new | $0 | – | -16,002 | -100.0% | -1.23% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-02-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| METTLER-TOLEDO INTL CMN | 20 | Q3 2019 | 4.7% |
| ALNYLAM PHARMACEUTICALS, INC. CMN | 20 | Q3 2019 | 5.0% |
| VERTEX PHARMACEUTICALS INC CMN | 20 | Q3 2019 | 4.0% |
| ILLUMINA, INC. CMN | 20 | Q3 2019 | 4.4% |
| SEATTLE GENETICS, INC. CMN | 20 | Q3 2019 | 4.0% |
| ALEXION PHARMACEUTICALS INC CMN | 20 | Q3 2019 | 4.3% |
| INCYTE CORPORATION CMN | 20 | Q3 2019 | 4.4% |
| NEKTAR THERAPEUTICS CMN | 20 | Q3 2019 | 4.9% |
| REGENERON PHARMACEUTICALS | 20 | Q3 2019 | 3.8% |
| CELGENE CORPORATION CMN | 20 | Q3 2019 | 3.8% |
View Opus Point Partners Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2019-11-14 |
| 13F-HR | 2019-08-14 |
| 13F-HR | 2019-05-15 |
| 13F-HR | 2019-02-14 |
| 13F-HR | 2018-11-14 |
| 13F-HR | 2018-08-14 |
| 13F-HR | 2018-05-15 |
| 13F-HR | 2018-02-14 |
| 13F-HR/A | 2017-11-17 |
| 13F-HR | 2017-11-14 |
View Opus Point Partners Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.